Terlipressin Injection Dosing Regimens
Hepatorenal Syndrome Type 1 (HRS-AKI)
For HRS-AKI, initiate terlipressin at 1 mg IV every 4-6 hours (total 4-6 mg/day) combined with albumin 1 g/kg on day 1 (maximum 100 g) followed by 20-40 g daily. 1 If serum creatinine fails to decrease by at least 25% from baseline by day 3, escalate to 2 mg every 4-6 hours (total 8-12 mg/day). 1 Continue treatment until serum creatinine returns to within ≤0.3 mg/dL of baseline for 2 consecutive days or for a maximum of 14 days. 1
Alternative Continuous Infusion Strategy
Alternatively, administer terlipressin by continuous IV infusion starting at 2 mg/day, which reduces ischemic side effects while maintaining efficacy. 1 Increase the dose gradually every 24-48 hours up to a maximum of 12 mg/day until HRS reversal occurs. 1 This approach allows lower total daily doses with fewer adverse events compared to bolus dosing. 2, 3
Critical Contraindications and Monitoring
Do not use terlipressin if serum creatinine ≥5 mg/dL or oxygen saturation <90%. 1, 4 Terlipressin is contraindicated in patients with hypoxia, worsening respiratory symptoms, or ongoing coronary, peripheral, or mesenteric ischemia. 5 Monitor closely for ischemic complications including angina, arrhythmia, splanchnic ischemia, and digital ischemia—discontinue immediately if these occur. 1 Respiratory failure occurred in 30% of patients in the CONFIRM trial, particularly those with concurrent organ failure or elevated baseline mean arterial pressure. 1
Response Predictors
Favorable response predictors include baseline bilirubin <10 mg/dL, baseline serum creatinine <5 mg/dL, lower acute-on-chronic liver failure stage, and sustained MAP increase of 5-10 mm Hg with treatment. 1 Patients with systemic inflammatory response syndrome, alcohol-associated hepatitis, and sepsis may respond better. 1
Acute Variceal Hemorrhage
For acute variceal hemorrhage, octreotide is the vasoactive drug of choice based on its superior safety profile. 5 However, if terlipressin is used (standard outside the United States, though not FDA-approved for this indication), administer 2 mg IV every 4 hours for the initial 48 hours until bleeding is controlled, then reduce to 1 mg IV every 4 hours for maintenance. 5, 6 Continue for 2-5 days total. 5, 6
Safety Concerns with Variceal Bleeding
Terlipressin carries a 2.39-fold increased risk of adverse events compared to octreotide or somatostatin in variceal hemorrhage. 5 Meta-analyses show terlipressin was less effective than octreotide for bleeding control within 24 hours and had higher complication rates than somatostatin. 5 Common adverse events include abdominal pain, chest pain, diarrhea, hyponatremia, nausea, respiratory failure, and dyspnea. 5
Emerging Continuous Infusion Data
Limited data from single-center RCTs in India suggest continuous terlipressin infusion at 4 mg/24 hours may be superior to bolus dosing (2 mg every 4 hours) for variceal bleeding, with lower rebleeding rates (2% vs 15%) and fewer adverse events. 5 However, this approach required hepatic venous pressure gradient monitoring at 12 and 24 hours for dose adjustment, which is not feasible in most settings. 5
Key Clinical Pitfalls
- Albumin is mandatory with terlipressin—never use terlipressin alone for HRS-AKI. 1 Monitor fluid status closely to avoid pulmonary edema from excessive albumin. 1
- Discontinue treatment if serum creatinine remains at or above baseline on day 4 despite maximum tolerated doses. 7, 4
- Do not resume terlipressin if ischemic symptoms occur, even if symptoms resolve after discontinuation. 1
- The FDA-approved dosing for HRS-AKI starts at 1 mg (0.85 mg terlipressin base) every 6 hours, with escalation to 2 mg (1.7 mg base) every 6 hours on day 4 if inadequate response. 4